MARKET

CTMX

CTMX

CytomX
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.25
+0.23
+2.55%
Pre Market: 9.15 -0.1 -1.08% 09:04 09/17 EDT
OPEN
9.00
PREV CLOSE
9.02
HIGH
9.37
LOW
8.91
VOLUME
164.93K
TURNOVER
--
52 WEEK HIGH
19.75
52 WEEK LOW
8.07
MARKET CAP
420.04M
P/E (TTM)
-4.2038
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CTMX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CTMX News

  • CytomX Therapeutics (CTMX) Presents At H.C. Wainwright 21st Annual Global Investment Conference - Slideshow
  • Seeking Alpha - Article.19h ago
  • Stocks That Hit 52-Week Lows On Wednesday
  • Benzinga.09/04 15:39
  • CytomX Therapeutics to Present at Upcoming Healthcare Conferences
  • GlobeNewswire.08/28 13:00
  • Stocks That Hit 52-Week Lows On Monday
  • Benzinga.08/26 14:28

More

Industry

Biotechnology & Medical Research
+0.98%
Pharmaceuticals & Medical Research
-0.14%

Hot Stocks

Name
Price
%Change

About CTMX

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies. Its product candidates include CX-072, CX-2009, CX-2029, Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and CX-188. Its Probody platform utilizes active proteases in tumor tissue to allow monoclonal antibody-based therapies. Its investigational Probody therapeutics address clinically validated cancer targets in immuno-oncology, such as programmed death-ligand 1, against which CX-072 is directed, as well as targets, such as cluster of differentiation 166, against, which CX-2009 is directed.
More

Webull offers CytomX Therapeutics Inc (CTMX) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.